hotspot -WSS

hotspot

author：knowledge 2025-09-07 17:27:59 - browse：176

Duchenne muscular dystrophy Histopathology — Duchenne muscular dystrophy histopathology. Dr. Edwin P. Ewing, Jr./CDC

Japanese drugmaker Nippon Shinyaku said on Monday that its Duchenne muscular dystrophy drug, Viltepso, part of a controversial class of treatments for the rare disease, had failed to reach its primary endpoint in a placebo-controlled confirmatory trial.

Children who received the drug could stand up faster from the floor at the end of the study, but so could children who received a placebo. There was no statistically significant difference between the groups.

Although Nippon did not release detailed data, the failure is notable because Viltepso belongs to a contentious class of drugs called exon-skippers. Duchenne is caused by mutations in a muscle-supporting gene called dystrophin. These drugs are designed to increase the amount of dystrophin protein that patients with specific mutations produce. But the drugs only lead to slight increases in protein levels, and their clinical benefits have never been proven in a large, placebo-controlled study.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： How the messy conversation about Dolly changed bioethics

Wikipedia

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

Transgender sports debate: Physicians say bans are health issue

Midwives could help bridge maternal health disparities in the U.S.

PBMs drew scrutiny in House hearing — and so did pharma

More doctors should go into startup world

Senate panel clears PBM, hopsital reforms

knowledge

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

Moonlake's readout produced a cash windfall. Risks remain

Why the drug industry's warnings on the IRA's impact fall short

As demand for Covid shots wanes, Moderna seeks its next success

Will General Catalyst be the first of many hospital takeovers?

Hollywood unions extend contract negotiations for actors

Medicare will require more price transparency from hospitals

Guidelines to prevent youth baseball injuries need more muscle

Victims of gun violence feel impacts long after bullet wound

Trump demands the U.S. pay no more for drugs than other countries … again

Bankrupt Pear's prescription app helped MassHealth save money, data suggests

leisure time

FDA panel to weigh safety of artificial wombs for preterm births

Medicare solvency divides Republicans at the presidential debate

Study: New antibiotic targets gonorrhea as well as last existing drug

Senate bill would ban some hospital facility fees

Akili changes sales model for its ADHD video game treatment

Study: New antibiotic targets gonorrhea as well as last existing drug

explore

knowledge

Wikipedia

leisure time